Head-to-head for women
Pallas Health vs ShedRx
Pallas Health and ShedRx both offer GLP-1 telehealth to women, but they make different trade-offs on PCOS and hormonal suitability, clinical oversight, price and access. Here they are side-by-side on the Luna Fit Score — our women's-health rubric.
Pallas Health
Ranked #16 for women · Grade B−
Luna Fit
Best for: Readers who want a general compounded GLP-1 program with unusually specific disclosure about who prescribes and who dispenses, and who can absorb a $597 charge four weeks after the $139 one — not readers looking for PCOS or perimenopause care, which Pallas does not offer.
Visit Pallas HealthShedRx
Higher scoreRanked #9 for women · Grade B
Luna Fit
Best for: Women who want an oral or sublingual option rather than weekly injections, at competitive tirzepatide pricing.
Visit ShedRxThe verdict for women
ShedRx edges out Pallas Health on the Luna Fit Score, 83 to 82 (B vs B−). Women who want an oral or sublingual option rather than weekly injections, at competitive tirzepatide pricing. The reasoning behind that number is in the ShedRx scorecard.
Pallas Health is still a genuine option — names its six dispensing pharmacies and two NPI-verified physicians — disclosure few rows here offer — and then sells the whole thing on a single 12-week prepay whose advertised “$199/mo average” is that prepay divided by three, with no monthly rung to pick instead. Weigh the six women's-health factors below against your own priorities; the Pallas Health scorecard goes through each of them, and if neither of these two is the one, the full field we rank against Pallas Health widens the field.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | Pallas Health | ShedRx |
|---|---|---|
| Luna Fit Score | 82/100 · B− | 83/100 · B |
| Overall rank | #16 | #9 |
| Semaglutide | $199/mo average — Pallas's own figure for $597 billed every 12 weeks, which is its only cadence; $139 covers the first 4 weeks, after which the next charge is $597 in one payment | $199/mo |
| Tirzepatide | $299/mo average — Pallas's own figure for $897 billed every 12 weeks, which is its only cadence; $179 covers the first 4 weeks, after which the next charge is $897 in one payment | $299/mo |
| Coverage | All 50 states and Washington D.C. — asynchronous in 43; Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and D.C. require one video visit | Not disclosed |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Luna Fit
Pallas Health
Ranked #16 · Grade B−
What we like
- Names all six dispensing pharmacies in public — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — with the 503A and 503B distinction explained, where almost everything else in this category names none
- Names two prescribing physicians with their NPI numbers and links out to the NPPES registry so you can check them yourself: Dr. Ana Lisa Carr, MD (family medicine, NPI-verified, licensed in 15 states) and Dr. Kelly Tenbrink, MD (emergency medicine, NPI-verified, Tennessee and Florida). Pallas additionally claims obesity and addiction medicine board certifications for Dr. Carr, which NPPES does not carry either way
- The advertised price is the checkout price — the homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same four figures, and no different number appears at payment
The caveats
- There is no month-to-month rung. The funnel renders no cadence selector at all: semaglutide is $139 for the first four weeks and then $597 billed every 12 weeks, so the second charge is $597 in one payment four weeks after the first — tirzepatide, $179 then $897 — and the advertised “$199/mo average” is that 12-week prepay divided by three rather than a price anyone is billed
- Twelve weeks is not three months. On Pallas's own published renewal terms the charge recurs every 84 days — 4.35 times a year, not four — so semaglutide's first year is $139 + 4×$597 = $2,527, or $210.58/mo, and the steady state is $2,596 a year, about $216/mo, against $199 advertised. Tirzepatide runs $3,767 in year one ($313.92/mo) and about $3,900 a year after (~$325/mo) against $299. The advertised average understates the ongoing rate by roughly 8.7%
- No women's-health program of any kind. Pallas's own women's-health category exists only as “coming soon”; there is no PCOS track, no perimenopause track and no cycle-aware protocol, and neither named physician is an OB-GYN or a women's-health specialist. What is on offer here is a general compounded GLP-1 program, and it should be read as one
Luna Fit
ShedRx
Ranked #9 · Grade B
What we like
- Offers oral/sublingual forms — a real alternative to weekly shots
- Competitive tirzepatide pricing
- Weight-focused program with titration support
The caveats
- States-served not disclosed
- Compounded only
- Hormonal/PCOS framing is general, not specialized
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. Pricing, states and verification reflect each provider's public disclosures at last review; the Luna Fit Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Neither Pallas Health nor ShedRx is only worth comparing with the other. Pallas Health is also written up against CoreAge Rx, 11 points apart on the Luna Fit Score — see Pallas Health against CoreAge Rx, factor by factor. ShedRx is also written up against CoreAge Rx, 10 points apart — see the ShedRx–CoreAge Rx head-to-head.
- Pallas Health vs CoreAge Rx
- Pallas Health vs Enhance MD
- Pallas Health vs yourEra
- ShedRx vs Sesame Care
- ShedRx vs HealthRX
- ShedRx vs MadeMed
Or browse the full comparison hub.